Flare Therapeutics

Flare Therapeutics is a pioneering biotechnology research company dedicated to discovering and developing precision medicines for cancer and other diseases. Flare Therapeutics is focused on drugging transcription factors to unlock the therapeutic potential of this previously elusive target class. Through its integrated discovery platform, Flare Therapeutics identifies novel validated ligands to the undrugged proteome.

Flare Therapeutics' lead program, FX-909, is a first-in-class orally available small molecule inhibitor of PPARG, a master regulator of the luminal lineage, initially being developed for locally advanced or metastatic urothelial cancer. FX-909 has achieved clinical proof-of-concept in a Phase 1A study as a monotherapy and is actively dosing patients in a Phase 1B study. The company's second lead program, FX-111, is a novel and highly differentiated potent and selective degrader for ARON, the transcriptionally active, hormone-bound androgen receptor.

Located in Cambridge, MA, at Cambridge , MA 02139, US, Flare Therapeutics is committed to advancing the field of precision medicine and improving patient outcomes. Flare Therapeutics is dedicated to innovation and excellence in all its endeavors. We invite the company's manager to create a customized and exclusive company showcase and product listing on our platform to further highlight Flare Therapeutics' groundbreaking work.